Pharma/BioTech Update: Biogen Idec’s Hemophilia Drug Price to Remain on Par
April 21, 2014; Posted by: WeBleed staff
Biogen Idec’s hemophilia B drug, Alprolix, price will be comparable to current factor therapies.
An article released today by FiercePharma stated that Biogen Idec’s new hemophilia B drug, Alprolix, will be priced similarly to older and current therapies. The once-weekly-or-less pharmaceutical will have similar costs to those of competitors in the hemophilia B market like Pfizer’s Benefix.
“In essence, Biogen appears to be more focused on getting the patient switches,” ISI Group analyst Mark Schoenebaum wrote about the pricing strategy.
Biogen Idec’s head of global commercial operations, Tony Kingsley, recently called Alprolix “a meaningful advance in a market that hasn’t seen a significant advance in a decade and a half.” With hemophilia B affecting only about 4-5,000 people in the United States, Biogen’s hemophilia A candidate, Eloctate, expects approval by the Food and Drug Administration (FDA) in the next few months. Analysts expect Eloctate to “control 37% of the adult market over the next two years” with companies like Baxter and Novo Nordisk also coming out with new hemophilia A therapies.
With all the new advancements, and with more to come, Alprolix is set for distribution next month in the United States.
Photo Credit – Biogen Idec
